PARIS & LES ULIS, France--(BUSINESS WIRE)--Regulatory News: Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) and CELLforCURE, the largest commercial industrial facility for the production of innovative therapeutic cell therapies in Europe, a subsidiary of the biopharmaceutical group LFB, announce that they have entered into an agreement for the cGMP manufacturing of clinical batches of Cellectis’ allogeneic CART cells.
Help employers find you! Check out all the jobs and post your resume.
